New hope for Hard-to-Treat cancers: experimental drug targets KRAS mutations
NCT ID NCT07094113
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This early-phase study tests a new drug, AMG 410, in people with advanced or spreading solid tumors that have a specific change in the KRAS gene. The main goals are to check safety, find the best dose, and see if the drug works alone or with other treatments. About 434 adults who have no other standard options will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS ALTERED ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
RECRUITINGMilan, 20162, Italy
-
Centre Leon Berard
RECRUITINGLyon, 69008, France
-
Centro Ricerche Cliniche Di Verona Societa responsabilita limitata
RECRUITINGVerona, 37134, Italy
-
Chris OBrien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Duke Cancer Center
RECRUITINGDurham, North Carolina, 27710, United States
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
-
Next Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
Next Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Peter MacCallum Cancer Centre
RECRUITINGParkville, Victoria, 3050, Australia
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
-
Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
-
Royal Marsden Hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
Sarah Cannon Research Institute Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sir Mortimer B Davis - Jewish General Hospital
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Siteman Cancer Center - Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
-
The Queen Elizabeth Hospital
RECRUITINGWoodville South, South Australia, 5011, Australia
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Universitaetsklinikum Essen
RECRUITINGEssen, 45147, Germany
-
Universitair Medisch Centrum Utrecht
RECRUITINGUtrecht, 3584 CX, Netherlands
-
Universitair Ziekenhuis Gent
RECRUITINGGhent, 9000, Belgium
Conditions
Explore the condition pages connected to this study.